Wellgistics Health, Inc. announced on February 26, 2025, that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC. This collaboration focuses on marketing Tollo’s proprietary suite of novel medical food products. These products address side effects related to GLP-1 treatments, such as muscle loss, and symptoms of Long COVID.
Tollo’s first marketed product, Galectovid™, is a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. Wellgistics LLC plans to assist Tollo in preparing marketing materials for its network of pharmacies. This initiative aims to educate healthcare practitioners on optimizing patient outcomes by incorporating these medical foods into treatment regimens.
This expansion into medical foods targets significant market opportunities, with the GLP-1 drug market valued at $46.7 billion and projected to grow to $322 billion by 2034. The agreement positions Wellgistics as a key supplier for healthcare professionals in these growing markets. It also supports the company's strategy to provide comprehensive solutions within its micro health ecosystem.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.